Alternatively, NKp46 (188), NKp44 (189), and NKp30 (190) have each been fused to generate second-generation CAR-T cells that further demonstrates the benefit of tumor recognition capability of natural NK ligands for anti-tumor efficacy. The gene discussed is NCR3; the disease is neoplasm.